The EPO published patent application EP3421009A1 for an aortic bare stent and aortic dissection stent system. The application, filed by Hangzhou Endonom Medtech Co., Ltd. (Hangzhou, China), claims priority to earlier dates and covers devices classified under A61F 2/07, A61F 2/915, and A61F 2/89. The patent is designated across all 38 EPC contracting states including Germany, France, UK, Italy, Spain, and other EU member states.

Patent publications do not impose compliance obligations on third parties. Medical device manufacturers and competitors in the aortic stent market should review the published claims to assess potential infringement risks or licensing opportunities. No action is required for most stakeholders. Competitors developing similar endovascular devices may need to design around the claimed stent configurations or seek cross-licensing arrangements with the patent holder.